Your Cart is Empty
BUY 1 GET 1 FREE · AUTO APPLIES AT CHECKOUT
⚠ Important | Secondary Raynaud's phenomenon is associated with underlying conditions (scleroderma, lupus, rheumatoid arthritis) that require physician management. CBD is not a treatment for Raynaud's. If you are on vasodilator medications (calcium channel blockers, sildenafil) for Raynaud's, discuss adding CBD with your physician before starting — additive vasodilation may require dose monitoring. PureCraft CBD products are broad-spectrum zero-THC, batch-verified at purecraftcbd.com/pages/faq.
By the PureCraft CBD Editorial Team | Updated 2026 | 11 min read
Raynaud's phenomenon is a vascular condition characterized by episodic vasospasm — exaggerated constriction of small blood vessels in the fingers, toes, ears, and nose in response to cold or emotional stress. During a Raynaud's attack, the affected digits turn white (ischemia from vasospasm), then blue (cyanosis from deoxygenation), then red (reactive hyperemia on reperfusion) — the classic triphasic color change. Attacks are painful, last minutes to hours, and in severe secondary Raynaud's can cause digital ulcers and ischemic tissue damage.
Raynaud's affects an estimated 5–10% of the general population. Primary Raynaud's (no underlying disease) is benign and most common in young women. Secondary Raynaud's is associated with autoimmune connective tissue diseases — most commonly scleroderma (systemic sclerosis), lupus, rheumatoid arthritis, and Sjögren's syndrome — and is more severe and more difficult to manage.
The endocannabinoid system is directly involved in vascular tone regulation — making CBD's vasodilatory and anti-inflammatory mechanisms mechanistically relevant to Raynaud's in a way that is not immediately obvious from CBD's most common applications.
Raynaud's vasospasm is driven by exaggerated sympathetic nervous system activation in digital blood vessels — specifically, alpha-2 adrenergic receptor (α2AR) hypersensitivity in digital arterioles. In cold or stress conditions, the sympathetic nervous system normally produces mild vasoconstriction to conserve core body heat. In Raynaud's, this vasoconstriction response is dramatically amplified — alpha-2 adrenergic receptors on digital arteriolar smooth muscle constrict far more aggressively than in people without the condition, producing the complete or near-complete blood flow cutoff that causes the characteristic color changes.
The cold-induced α2AR hypersensitivity in Raynaud's is also temperature-dependent in a counterintuitive way: α2AR sensitivity increases at lower temperatures through a cold-sensitive signaling pathway involving Rho-kinase activation. This Rho-kinase component is one reason calcium channel blockers (which block calcium-mediated smooth muscle contraction) are effective for Raynaud's — they reduce the downstream smooth muscle contraction regardless of the upstream adrenergic trigger.
Beyond sympathetic hyperreactivity, Raynaud's involves endothelial dysfunction — impaired production of nitric oxide (NO), the primary endothelium-derived vasodilator. In healthy vasculature, NO continuously counterbalances vasoconstrictive signals, maintaining basal vasodilation and preventing inappropriate vasoconstriction. In Raynaud's — particularly secondary Raynaud's — endothelial NO production is reduced, removing this vasodilatory counterbalance and making digital vessels more vulnerable to vasospasm from adrenergic triggers. This is the rationale for PDE5 inhibitors (sildenafil/Revatio) in severe Raynaud's: they amplify NO signaling by preventing its degradation.
In secondary Raynaud's — particularly in scleroderma — vascular inflammation and endothelial damage from the underlying autoimmune process compound the functional vasospasm with structural vascular disease. Inflammatory cytokines (TNF-α, IL-1β, IL-6) reduce endothelial NO production, promote vascular smooth muscle proliferation, and drive progressive vascular fibrosis. This vascular inflammatory component makes secondary Raynaud's mechanistically more complex than primary Raynaud's and explains why anti-inflammatory approaches have rational appeal beyond purely vasodilatory interventions.
CBD's most directly relevant Raynaud's mechanism is CB1-mediated endothelium-dependent vasodilation. CB1 receptors are expressed on vascular endothelial cells and smooth muscle — CBD's modulation of endocannabinoid tone (via FAAH inhibition raising anandamide) activates CB1 on endothelial cells, increasing endothelial nitric oxide synthase (eNOS) activity and NO production. This directly addresses the endothelial NO deficit that removes vasodilatory counterbalance in Raynaud's.
The Shannon et al. (2017) single-dose human study demonstrating a 6 mmHg systolic blood pressure reduction with CBD (600mg dose) was mediated in part through this endothelium-dependent NO mechanism — the same mechanism relevant to digital vascular tone in Raynaud's. At lower supplement doses (15–25mg), the vasodilatory effect is considerably more modest, but consistent daily use may contribute to improved baseline vascular tone over time.
Raynaud's vasospasm is triggered not only by cold but by emotional stress — a well-documented Raynaud's trigger that operates through the same α2AR sympathetic pathway as cold. Chronic HPA dysregulation maintains elevated sympathetic tone — sustaining α2AR sensitivity and lowering the threshold for vasospastic attacks in stressful environments. CBD's progressive HPA recalibration reduces chronic sympathetic activation at the CRH and adrenergic axis level, potentially raising the stress threshold for Raynaud's attacks and reducing attack frequency in stress-sensitive individuals.
This HPA mechanism is most relevant for people whose Raynaud's attacks are predominantly stress-triggered rather than cold-triggered — a clinically distinct subgroup where anxiolytic and HPA-modulating interventions are most directly applicable.
For secondary Raynaud's — particularly scleroderma-associated — CBD's CB2-mediated anti-inflammatory effects address the vascular inflammatory component that compounds functional vasospasm with structural damage. CB2 receptor activation reduces the TNF-α, IL-1β, and IL-6 production that impairs endothelial NO generation and promotes vascular smooth muscle proliferation. This anti-inflammatory CB2 mechanism is not a standalone treatment for scleroderma vascular disease — the underlying autoimmune process requires immunosuppressive therapy — but it provides adjunctive anti-inflammatory coverage that standard Raynaud's vasodilator therapy does not.
TRPV1 channels — the primary temperature and pain sensors in peripheral nerves — are also expressed in vascular tissue and play a role in the cold sensitivity of Raynaud's. TRPV1 in digital blood vessels responds to cold through mechanisms that intersect with the α2AR vasospastic pathway. CBD's TRPV1 partial agonism/desensitization may modulate the cold-triggered vascular response at the TRPV1 level in addition to its central HPA and endothelial NO mechanisms. This mechanism is the least clinically characterized of CBD's Raynaud's-relevant pathways — preclinical in nature — but adds a fourth mechanistic angle to CBD's potential vascular benefit.
Raynaud's involves endothelial NO deficit, sympathetic hyperreactivity, and vascular inflammation. CBD's CB1 NO production, HPA sympathetic reduction, and CB2 anti-inflammatory activity address all three — through mechanisms orthogonal to calcium channel blockers.
| Feature | Primary Raynaud's | Secondary Raynaud's | CBD Priority |
|---|---|---|---|
| Underlying disease | None | Scleroderma, lupus, RA, Sjögren's | CB2 anti-inflammatory more important in secondary |
| Severity | Mild-moderate | Moderate-severe; digital ulcers possible | CBD adjunct; secondary requires prescribed vasodilators |
| Primary trigger | Cold; sometimes stress | Cold + structural vascular disease | HPA more relevant for stress trigger; CB1/NO for cold |
| Standard treatment | Lifestyle (warmth, stress management); sometimes CCBs | CCBs, PDE5 inhibitors, prostacyclin; underlying disease treatment | CBD interaction with CCBs and PDE5i — additive vasodilation; disclose to physician |
| CBD interaction risk | Low — lifestyle management only | Moderate — vasodilator medications; disclose to physician | CCBs: CYP3A4 interaction (see P8-10); PDE5i: CYP3A4 overlap |
Calcium channel blockers (amlodipine, nifedipine) — the most commonly prescribed medications for Raynaud's — are CYP3A4 substrates. CBD's CYP3A4 inhibition can raise CCB blood levels, producing additive vasodilation. For people on CCBs for Raynaud's, adding CBD requires physician disclosure and monitoring for hypotension, dizziness, or excessive vasodilation — the same considerations covered in detail in P8-10 (CBD and Blood Pressure Medications). Start CBD at a low dose (10–15mg) and monitor blood pressure.
PDE5 inhibitors (sildenafil/Revatio) — used for severe Raynaud's and scleroderma-associated pulmonary hypertension — are also CYP3A4 substrates. CBD's CYP3A4 inhibition could raise sildenafil levels, potentially intensifying vasodilation and hypotension. Physician disclosure is required before combining CBD with sildenafil for Raynaud's.
Bosentan — used in severe scleroderma-associated Raynaud's — is a CYP3A4 substrate and inducer; the interaction profile with CBD is complex and requires specialist input.
Mechanistically, yes — CBD's CB1-mediated endothelial NO production, HPA reduction of sympathetic tone, and CB2 anti-inflammatory effects address three of the four primary vascular dysfunction mechanisms in Raynaud's. No Raynaud's-specific CBD clinical trials exist; the evidence is mechanistic and from adjacent vascular research (Shannon 2017 blood pressure trial). For primary Raynaud's where lifestyle management is the standard approach, CBD represents a reasonable adjunct with low risk. For secondary Raynaud's on vasodilator medications, physician disclosure is required before adding CBD.
Primary Raynaud's has no underlying disease — it is a standalone vascular hyperreactivity condition, most common in young women, typically mild and managed with warmth and stress reduction. Secondary Raynaud's is caused by an underlying condition — most commonly scleroderma (systemic sclerosis), lupus, RA, or Sjögren's syndrome — and is more severe, more difficult to treat, and can cause digital ulcers and permanent vascular damage. Secondary Raynaud's requires treatment of the underlying condition alongside specific vasodilator therapy, and CBD use requires physician oversight given the complexity of the medication regimen.
Yes — calcium channel blockers (amlodipine, nifedipine) are CYP3A4 substrates, and CBD inhibits CYP3A4, raising CCB blood levels. Combined with CBD's own vasodilatory effect through CB1 and NO, the combination can produce additive hypotension. This interaction is manageable with physician oversight — start CBD at low dose, monitor blood pressure, and report any dizziness or unusual lightheadedness. The full CCB interaction is covered in P8-10 (CBD and Blood Pressure Medications).
Yes — emotional stress is a well-documented Raynaud's trigger through the same α2AR sympathetic pathway activated by cold. Stress management (mindfulness, biofeedback, CBT for anxiety) reduces sympathetic tone and demonstrably reduces Raynaud's attack frequency in stress-sensitive individuals. CBD's HPA recalibration and 5-HT1A anxiolytic mechanisms are a pharmacological complement to behavioral stress management — reducing the sympathetic baseline that makes stress-triggered attacks more likely. For people with predominantly stress-triggered Raynaud's, CBD's anxiolytic profile is the most directly relevant mechanism.
The mechanistic case for topical CBD on hands and digits before cold exposure is plausible — CB1 receptors on digital vascular endothelium are local targets that topical application can reach more directly than systemic oral dosing. The evidence specifically for topical CBD in Raynaud's vasospasm does not exist in clinical trials; the rationale is mechanistic. Some Raynaud's patients report subjective benefit from topical CBD applied before cold exposure — this is consistent with the CB1/TRPV1 vascular mechanisms, though placebo effects are difficult to exclude without controlled trials. Topical CBD is safe, carries no interaction risk, and the mechanistic case supports its use as a reasonable adjunct.
Scleroderma-associated Raynaud's is severe and involves both functional vasospasm and structural vascular disease from the underlying autoimmune process. CBD's CB2 anti-inflammatory activity is relevant to the vascular inflammatory component; its CB1 NO mechanism addresses the endothelial dysfunction that is particularly pronounced in scleroderma vascular disease. However, scleroderma-associated Raynaud's requires specialized rheumatological management — prescribed vasodilators (CCBs, PDE5 inhibitors, prostacyclin analogues), and often immunosuppressive therapy for the underlying scleroderma. CBD should be considered an adjunct within this specialist-managed framework, not an independent treatment strategy.
Raynaud's phenomenon involves three vascular dysfunction mechanisms — endothelial NO deficit, sympathetic hyperreactivity, and (in secondary Raynaud's) vascular inflammation — that map onto CBD's CB1, HPA, and CB2 mechanisms respectively. No Raynaud's-specific CBD trials exist, but the mechanistic alignment is clear and the adjacent vascular evidence (CBD's documented blood pressure-reducing vasodilatory effect) is directly relevant. For primary Raynaud's managed with lifestyle measures, CBD is a low-risk adjunct worth trying. For secondary Raynaud's on vasodilator medications, physician disclosure and interaction monitoring are required — particularly with CCBs and PDE5 inhibitors where CYP3A4 interaction risk is real.
PureCraft CBD Oil — 15–20mg AM daily; 10mg if on CCBs. Topical CBD for hands before cold exposure. CBD+CBN Sleep Gummies nightly. Zero THC, batch-tested COA. Browse all PureCraft CBD products.
Medical Disclaimer | CBD is not a treatment for Raynaud's phenomenon. Secondary Raynaud's requires physician management of the underlying condition. If you are on vasodilator medications, discuss adding CBD with your physician before starting. PureCraft CBD products are not intended to diagnose, treat, cure, or prevent any disease.
⚠ Important | Ehlers-Danlos syndrome is a complex connective tissue disorder requiring specialist management. CBD is not a treatment for EDS. Disc...
Read More
⚠ Important | Binge eating disorder is a serious psychiatric condition requiring clinical evaluation and evidence-based treatment — typically cogn...
Read More
⚠ Important | Ankylosing spondylitis is a serious autoimmune condition requiring physician management. CBD is not a treatment for AS and does not ...
Read More